HC Wainwright Reaffirms “Buy” Rating for Ekso Bionics (NASDAQ:EKSO)

Ekso Bionics (NASDAQ:EKSO)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright also issued estimates for Ekso Bionics’ FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.12 EPS and FY2029 earnings at $0.46 EPS.

Separately, StockNews.com began coverage on Ekso Bionics in a report on Monday. They issued a “hold” rating on the stock.

Ekso Bionics Trading Down 8.0 %

EKSO opened at $0.44 on Tuesday. Ekso Bionics has a one year low of $0.37 and a one year high of $1.64. The company has a market cap of $9.64 million, a P/E ratio of -0.67 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The business’s 50-day simple moving average is $0.61 and its 200-day simple moving average is $0.82.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. As a group, equities research analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.